StockpollyBeta
Get App
Popularity #2,796
LRMR · NASDAQ · Biotechnology

Larimar Therapeutics (LRMR)

Develops nomlabofusp to deliver frataxin in Friedreich's ataxia.

$3.73
vs last close−0.10 (−2.49%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
101417251831312849643134
Research & development71113201427272345592528
444545545566
Selling & marketing000000000000
General & administrative444545545566
Other expenses000000000000
Operating income−10−14−17−25−18−31−31−28−49−64−31−34
112332222222
Other non-operating income0−1−2−3−3−2−2−2−2−2−2−2
Income before tax−9−13−15−22−15−29−29−26−48−62−30−33
Net income from continuing operations−9−13−15−22−15−29−29−26−48−62−30−33
Net income−9−13−15−22−15−29−29−26−48−62−30−33
EPS, basic−$0.21−$0.30−$0.27−$0.34−$0.24−$0.45−$0.46−$0.41−$0.61−$0.73−$0.35−$0.30
EPS, diluted−$0.21−$0.30−$0.27−$0.34−$0.24−$0.45−$0.46−$0.41−$0.61−$0.73−$0.35−$0.30
Weighted average shares, basic4444546464646464788585104
Weighted average shares, diluted4444546464646464788585104
EBITDA−10−13−15−22−15−29−29−26−48−62−30−33
Depreciation & amortization000000000000
EBIT−10−13−15−22−15−29−29−26−48−62−30−33